Head of Hemoglobinopathy Programs
Ms. Krista McKerracher brings to CRISPR Therapeutics over 30 years of experience in the pharmaceutical and biotech industry. She has deep knowledge of thalassemia and sickle cell disease gained from her role as Vice President & Global Program Franchise Head at Novartis Oncology Global Development. At Novartis, she led the team that developed Exjade® and Jadenu® for transfusional iron overload and grew them into a $1 billion asset. She also led the phase 2 collaboration on crizanlizumab for sickle cell disease, and led the acquisition of the compound into Novartis. As a drug developer, she brings a strong commercial orientation, ensuring programs are designed with the label and pricing dossier in mind. Prior to Novartis, Krista spent 14 years at the Johnson & Johnson family of companies in Canada and the U.S.
Krista has a B.Sc. (Hon) in Applied Health Studies from the University of Waterloo and an M.B.A. from the Schulich School of Business at York University.